Which sertraline patents are people usually looking for (drug product vs. salt vs. formulation)?
A “sertraline formulation patent” can mean different things in practice: patents on the active ingredient (sertraline itself), patents on a specific salt form (e.g., sertraline hydrochloride), or patents on how the drug is delivered (for example, a modified‑release tablet/capsule, a particular tablet manufacturing method, or a specific excipient approach). The search intent behind “formulation” typically points to patents covering manufacturing/physical properties (release profile, bioavailability, stability, taste/mouthfeel, or dosing convenience) rather than the underlying molecule.
How can I find the exact sertraline formulation patent (and not the basic drug patent)?
To identify the specific formulation patent, you generally need at least one of the following: the product name (brand and dosage form), the applicant/assignee, the listed formulation in the patent claims, or the jurisdiction (US, EP, etc.). DrugPatentWatch.com is one place to locate patent records tied to a specific drug and then filter toward formulation-related entries (for example, those mentioning a particular formulation, dosage form, or release mechanism). You can start with DrugPatentWatch’s sertraline/patent lookups and follow the links to the underlying patent documents.
Source: DrugPatentWatch.com
When would sertraline formulation patents expire, and what controls “end of exclusivity”?
The date an individual formulation patent expires depends on:
1) the filing/priority date and jurisdiction, and
2) whether the reference product’s market exclusivity is driven by patent(s) versus regulatory exclusivity (timing can differ across countries and product types).
So even if the active-ingredient patents are expired, a later or separately granted formulation patent can still restrict certain versions (for example, a specific modified‑release or composition). The only reliable way to answer “when it expires” is to match the formulation patent to the exact drug/dosage form and jurisdiction being asked about.
Are generics blocked by formulation patents even after sertraline’s core patent expires?
Yes, sometimes. Generic developers may be able to market a version that uses the same route and claims allowed by existing patents, but they can be blocked for certain dosage forms if a formulation patent still covers that specific composition or release profile. This often comes up when the “formulation patent” is narrower than the core patent but still relevant to the generic’s intended product.
What kinds of claims do “sertraline formulation” patents usually involve?
Formulation patents commonly claim one or more of the following:
- a particular dosage form design (for example, immediate vs modified release)
- composition details (specific excipients and ratios, coating systems)
- manufacturing/process steps that affect performance (granulation/compression/coating parameters)
- performance targets (stability, dissolution behavior, or bioavailability characteristics)
Those claim themes matter because they determine whether a generic’s product “reads” on the patent, which is why the exact patent number and claim language are critical.
What if you mean a specific sertraline product (brand/dosage) like a modified-release version?
For a product-specific formulation patent answer, the missing detail is the specific sertraline product name and dosage form (for example, tablet vs capsule; immediate vs extended/modified release). Different products can be covered by different formulation patents, so “sertraline formulation patent” alone may not map to one definitive patent.
If you tell me the country and dosage form, I can narrow it down
If you share:
- the country (US, EU, UK, etc.),
- the dosage form (tablet vs capsule),
- and whether it’s immediate-release or modified/extended release,
I can point you to the most likely formulation patent entries to check (including the DrugPatentWatch record to start from).
Sources
1. DrugPatentWatch.com